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Myeloablative chemotherapy and stem cell transplantation in
myeloma or primary amyloidosis with renal involvement.
Background. High-dose chemotherapy and stem cell trans-
plantation are being applied increasingly to the treatment of
selected patients with multiple myeloma or primary systemic
amyloidosis. Stem cell transplantation presents unique chal-
lenges to the nephrologist because of the high prevalence of
renal involvement in myeloma and the issues that are associated
with high-dose chemotherapy in patients with the nephrotic syn-
drome due to renal amyloid.
Methods. We review the published literature on stem cell
transplantation in patients with reduced renal function.
Results and Conclusions. The specifics of transplantation per-
taining to patients with renal amyloid nephrotic syndrome are
discussed in detail.
MULTIPLE MYELOMA
Multiple myeloma accounts for 1% of malignancies
and 10% of hematologic malignancies. In the United
States, the incidence of multiple myeloma is approxi-
mately 4.1/100,000 per year, and approximately 15,270
individuals in the United States developed and 11,070
died of this disorder in 2004 [1]. The median age of
patients at diagnosis is 66 years. The disease remains
incurable except for the small subset of patients who
are candidates for and survive allogeneic transplanta-
tion. A small globulin spike is found in the urine in
60% of multiple myeloma patients, and frequently mon-
oclonal light chains are toxic to the renal tubule, caus-
ing so-called myeloma cast nephropathy with tubular
obstruction, anuria, and azotemia. Patients with multi-
ple myeloma frequently develop renal insufficiency due
to hypercalcemia. The median urine monoclonal protein
in patients with multiple myeloma is 0.48 g/24 hours, and
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two thirds of patients excrete more than 200 mg/day. The
median serum creatinine concentration at presentation
is 106 lmol/L, 29% of patients present with a serum cre-
atinine value from 106 to 176 lmol/L, and 19% have a
creatinine value greater than 176 lmol/L at presentation
[2]. Renal failure does not appear to impact the response
rate to therapy, but if renal failure does not respond to
therapy for myeloma, survival is shorter [3].
The standard therapy for multiple myeloma has moved
increasingly toward autologous stem cell transplanta-
tion. Two prospective randomized studies have shown a
survival advantage for patients who receive a sin-
gle autologous transplant compared with conventional
chemotherapy [4, 5], and one prospective randomized
study [6] has shown a survival advantage for patients
who receive tandem (two consecutive) stem cell trans-
plantation compared with a single autologous stem cell
transplantation. The first randomized study showing the
superiority of transplantation included only a few pa-
tients with renal dysfunction, but the serum creatinine
concentration had to be less than 150 lmol/L before trans-
plantation. Recently, tandem transplantation showed a
superior survival compared with oral chemotherapy in
patients aged 60 to 70 years [7].
In the case of high-dose chemotherapy with stem cell
transplantation in patients with renal dysfunction, anec-
dotal and case series provide information regarding toxi-
city, but there are no prospective studies that definitively
clarify the effect high-dose chemotherapy with stem cell
transplantation has in these patients with regard to qual-
ity of life or overall survival. As a point of reference,
reversal of renal failure in myeloma patients treated with
conventional chemotherapy resulted in survivals not dif-
ferent from that of treated patients without renal failure
in a study of 88 patients with a serum creatinine concen-
tration more than 180 lmol/L. Though improvement in
renal function was seen in 51% of patients and in only
24% of those with cast nephropathy, a survival prolon-
gation was not seen compared with those conventionally
treated patients whose renal function did not improve
[3]. Because dose-intensive chemotherapy can be admin-
istered to selected patients whose age is up to 73 years [8],
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Table 1. Transplantation in myeloma patients with renal failure
Number of Treatment-related Event-free Overall Number on
Reference patients mortality% survival survival dialysis
Ballester et al [15] 6 17 4 (6-39 months) 4
San Miguel et al [16] 14 29 56% at 3 years
Tosi et al [17] 6 0 5/6 responders 1
Mikhael et ala 21 14 11
Badros et al [18] 81 51% at 3 years 60% at 3 years 38
Sirohi et alb 6 50 6
aMikhael JR, Mazaheri R, Sutton DM, et al: Feasibility of high-dose therapy and autologous stem cell transplantation in multiple myeloma patients with severe renal
failure [abstract]. Blood 98 (Pt 1):199a, 2001.
bSirohi B, Powles R, Kulkarni S, et al: Feasibility of administering high-dose melphalan (HDM) with autotransplantation in myeloma patients on dialysis [abstract].
Blood 98 (Pt 2):399B, 2001.
the majority of patients with multiple myeloma are can-
didates for high-dose therapy. In the Mayo Clinic series,
the median age at transplantation is 57 years and only
4% are age 70 years or older. Younger patients with hu-
man leukocyte antigen (HLA)-matched donors may be
candidates for allogeneic stem cell transplantation, which
poses additional challenges. Care of these patients will di-
rectly involve collaboration between hematologists and
nephrologists [9].
Autologous stem cell transplantation in myeloma
patients with renal insufficiency
The primary chemotherapeutic agent administered to
patients with multiple myeloma is melphalan at doses
ranging from 140 to 200 mg/m2. Doses as high as 280
mg/m2 have been administered, with a suggestion that
dose escalation may result in higher response rates
[10]. The pharmacokinetics of high-dose melphalan in-
dicate that the half-life and the area under the curve
are correlated significantly with creatinine clearance, al-
though there are great interindividual variations. Re-
nal insufficiency does not lead to a large decrease in
melphalan clearance compared to the interindividual
variations in systemic clearance [11]. In a prospective
study, six patients whose creatinine clearance was less
than 40 mL/min, including five on chronic hemodialy-
sis, received 200 mg/m2 of melphalan over 2 consecu-
tive days. The median half-life of the melphalan was
1.1 hours, and the clearance of the drug was 27.5 L/hour
in patients whose creatinine clearance was less than 40
mL/min. Renal insufficiency had no negative impact on
the quality of stem cell collections, stem cell engraft-
ment, mucositis, or overall survival but did result in
longer hospitalization [12]. Novel conditioning regimens
can also cause problems unique to myeloma patients.
The use of 166holmium-1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetramethylene-phosphonic acid (DOTMP) plus
melphalan to condition patients with multiple myeloma
can cause renal endothelial damage and renal failure due
to a thrombotic microangiopathy [13]. In one study, 30%
of patients conditioned with 166holmium-containing reg-
imens experienced grade 2 to 4 renal toxicity that led to
dialysis-dependent renal failure in 14 of 83 patients (17%)
treated. Hemorrhagic cystitis is also seen in patients con-
ditioned with holmium-containing regimens [14]. Six pa-
tients with multiple myeloma and renal insufficiency,
including 4 on dialysis, were conditioned with busulfan
and cyclophosphamide followed by autologous stem cells.
One of the patients who achieved a complete response
showed progressive recovery of renal function with a re-
duction in creatinine from 678 lmol/L to 352 lmol/L.
Renal failure produced no difficulty in the procurement
of stem cells [15] (Table 1).
Blade´ et al [19] reported on outcomes in 94 myeloma
patients with renal failure treated with standard-dose
chemotherapy. When patients who died within the first
2 months of therapy were excluded, there were no signif-
icant differences in the response rates between patients
with renal failure and those with normal renal function.
The serum creatinine level, however, did correlate with
survival. In patients whose creatinine value was greater
than 177 lmol/L, the overall median survival was 8.6
months [19].
The Spanish myeloma group reported on patients with
myeloma and renal insufficiency who underwent stem cell
transplantation. The first group presented at diagnosis
with renal insufficiency but had recovered renal function
at the time of stem cell transplantation. The second group
included patients who had persistent renal insufficiency at
the time of transplantation. Treatment-related mortality
in the renal failure patients depended on three variables:
(1) Eastern Cooperative Oncology Group performance
status of 3 or more, (2) a hemoglobin concentration of
less than 95 g/L, and (3) a serum creatinine value greater
than 440 lmol/L. Renal failure was not an exclusion factor
for transplantation. No dose modification of chemother-
apy was made, which may have contributed to the high
treatment-related mortality [16].
The myeloma group from Bologna, Italy, reported
their results on six renal failure patients. No patients
showed a decline of renal function through the transplan-
tation. The median pretransplantation creatinine clear-
ance for the six patients was 20 mL/min. The median
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posttransplantation creatinine clearance for the six pa-
tients was 60 mL/min. Pretransplantation, four of the six
patients had a creatinine clearance less than 30 mL/min.
Posttransplantation, only one patient had a creatinine
clearance less than 30 mL/min [17].
The Princess Margaret Hospital group reported out-
comes in renal failure patients. The mean creatinine value
for patients not on dialysis was 232 lmol/L (range 177 to
343 lmol/L). Median duration of hospitalization was 21
days. None of the patients who were dialysis dependent at
the time of transplantation had significant improvement
in their renal function. None of the patients who were
dialysis independent developed worsening renal function
from the transplantation procedure [abstract; Mikhael
JR, et al, Blood 98 (Pt 1):199a, 2001].
The largest experience has been reported from the
Myeloma Center of Little Rock, Arkansas. Eighty-one
patients with serum creatinine concentration greater than
176 lmol/L were reported. There was no difficulty in mo-
bilizing stem cells. Sixty patients, 27 of whom were on
dialysis, received full-dose melphalan of 200 mg/m2. Be-
cause of excessive toxicity, subsequent patients received a
reduced dose of 140 mg/m2. Patients who received trans-
plants and the melphalan dose of 200 mg/m2 had a sig-
nificantly higher incidence of pulmonary complications
(57% vs. 17%), hypotension (25% vs. 5%), and mucosi-
tis (93% vs. 67%). The patients on hemodialysis had a
higher incidence of pulmonary complications (53% vs.
19%), neurologic complications (47% vs. 6%), and skin
rash (75% vs. 10%) than those not on hemodialysis. Two
patients discontinued dialysis after stem cell transplan-
tation. Dialysis dependency did not affect event-free or
overall survival [18].
The transplant-related mortality was 6% after the first
and 16% after the second transplant. The complete hema-
tologic response rate was 27% after the first transplant
and 38% after the second transplant. There was no dif-
ference in complete response or event-free survival be-
tween melphalan 200 mg/m2 and melphalan 140 mg/m2,
and the latter was less toxic.
Twenty-seven of our patients whose serum creatinine
concentration was greater than 176 lmol/mL have un-
dergone transplantation. Five of the 27 died before day
100. Four of the five had advanced multiply relapsed dis-
ease, and their deaths were not related directly to the
renal failure. Two of the five had pulmonary aspergillo-
sis related to extensive prior therapy with corticosteroids
before transplantation. One patient died on day −1 of
fulminant sepsis. Median survival posttransplantation is
27 months.
Among 42 patients with renal failure and 84 pair-
matched controls with normal renal function, response
rates and 3-year actuarial survivals were comparable in
the two groups [20]. Patients on dialysis, when condi-
tioned appropriately, can have similar outcomes to pa-
tients with less-impaired renal function [21, 22].
Although the disease-free survival appears compa-
rable in renal-impaired myeloma patients and patients
with normal renal function, recovery of renal function
is uncommon, and patients with end-stage renal disease
(ESRD) continue to be dialysis dependent. Two patients
with myeloma who required hemodialysis at diagnosis
became dialysis independent after high-dose melphalan
and autografting. Low serum albumin concentration may
predict transplant-related complications in renal failure
patients treated with high-dose melphalan, an issue par-
ticularly relevant to amyloid patients [23].
Six myeloma patients on dialysis (age 50 to 65 years)
received melphalan 200 mg/m2 in four and melphalan
140 mg/m2 in two. Grade 3 to 4 mucositis developed in
all of the patients, and four had bacteremia. Atrial fibril-
lation developed in four. Three of four patients receiv-
ing melphalan 200 mg/m2 died of toxic responses in the
first month. Both of the patients receiving melphalan 140
mg/m2 survived [abstract; Sirohi B, et al, Blood 98 (Pt
2):399B, 2001].
The current transplantation guidelines for patients with
myeloma developed by the Cancer Care Ontario Practice
Guidelines Initiative acknowledge that autologous trans-
plantation is feasible in patients with serious renal dys-
function, but no prospective randomized studies indicate
a survival benefit compared with conventional therapy.
They did not recommend that transplantation be con-
sidered standard therapy for patients whose creatinine
value was greater than 150 lmol/L until randomized tri-
als demonstrate a survival benefit for these patients. If re-
nal dysfunction seen at diagnosis improves with induction
therapy, the patients should be considered subsequently
for high-dose therapy [24].
Morbidity is acceptable in patients who are on stable
dialysis or who have stable mild chronic renal insuffi-
ciency when they come to transplantation. The situation
is altered dramatically if acute renal failure develops dur-
ing transplantation, requiring dialysis support during the
first 30 days after conditioning. In a cohort of 97 consecu-
tive allogeneic blood and marrow transplant patients, 20
(21%) developed acute renal failure, Bearman grade 3.
All died by day +132. The renal failure was a contribut-
ing cause or the primary cause of death in 18 of the 20
patients developing renal insufficiency. The presence of
renal insufficiency strongly favors an autologous stem cell
source [25].
Rarely, the kidney is a target for the development
of graft-versus-host disease after allogeneic transplanta-
tion for myeloma. Nephrotic syndrome and membranous
glomerulonephritis developed in one patient as manifes-
tations of graft-versus-host disease after transplantation
for multiple myeloma [26].
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A patient who received a HLA-mismatched cadav-
eric donor renal transplant [27] for mesangial capil-
lary glomerulonephritis developed multiple myeloma as
a posttransplantation lymphoproliferative disorder 10
years after his kidney transplantation. Ultimately, the pa-
tient received an autologous peripheral blood stem cell
transplant followed by a continuous complete remission 2
years later. Epstein-Barr virus–related multiple myeloma
occurring after solid organ transplantation has been re-
ported recently in three patients and must be considered
a rare complication of solid organ transplantation [28].
In summary, there are no randomized studies that
answer the question of whether renal failure patients
receiving high-dose therapy benefit in terms of relapse-
free and overall survival. Renal failure patients do not
have impaired ability to mobilize stem cells or to en-
graft. Whether the disease control achieved by high-dose
therapy outweighs increased treatment-related mortal-
ity cannot be proved, but it appears that reducing the
dose of melphalan to 140 mg/m2 reduces the morbidity
to acceptable levels for most patients with renal failure.
These patients should be considered for immediate stem
cell mobilization followed by high-dose chemotherapy, as
outcomes in heavily pretreated patients result in mortal-
ity up to 21%.
AMYLOIDOSIS
Amyloidosis involving the kidney produces even
greater challenges for the nephrologist. Nephrotic syn-
drome is the most common indication for autologous
stem cell transplantation and is associated with the best
outcome. Fifty-six percent of patients with amyloido-
sis excrete more than 1 g of protein in a 24-hour pe-
riod, and 44% manifest nephrotic-range proteinuria. The
high prevalence of hypoalbuminemia predisposes them
to postconditioning renal insufficiency and excessive fluid
shifts. The entire process surrounding autologous pe-
ripheral blood stem cell transplantation—mobilization,
chemotherapy conditioning, stem cell infusion, and the
chemotherapy toxicity period—poses unique challenges,
including excessive fluid retention, cardiac arrhythmia,
renal failure, and gastrointestinal hemorrhage.
Among the first 171 patients who received autologous
peripheral blood stem cell transplants for primary sys-
temic amyloidosis at Mayo Clinic, the serum creatinine
concentration ranged from 53 to 345 lmol/L. The median
serum creatinine value was 97 lmol/L, and 9% of patients
with a serum creatinine value greater than 177 lmol/L re-
ceived transplants. The 24-hour urine protein excretion
ranged from 20 mg to 26 g/24 hours. The median 24-hour
urine protein loss for the entire group was 3.7 g, 64% or
110 patients lost more than 1 g of protein in the urine for
24 hours, and 56% or 95 patients lost more than 3 g for
the 24-hour period. Median age at transplantation was
55 years, ranging from 31 to 71 years. The serum albumin
value ranged from 10 to 44 g/L (median 28 g/L). Twenty-
five percent of patients had an albumin value less than
20 g/L, values that are quite relevant to the subsequent
toxicity seen. We and others have reported the ability
of high-dose therapy followed by autologous blood stem
cell transplantation to produce regression of nephrotic
syndrome in patients with amyloidosis. In fact, the fre-
quency of response is at least double that seen with more
traditional chemotherapy such as melphalan and pred-
nisone. A response has a profound impact on outcome.
Among our 171 patients, 117 responded (68%), and only
12 of those have died to date. The median survival of re-
sponders has not been reached, but their median survival
will exceed 6 years. Response is an important predictor
of overall survival.
Response in patients with amyloidosis is a two-part
concept. Responses are often divided into hematologic
and organ. The former uses the same monoclonal protein
and bone marrow variables used in determining response
in patients with multiple myeloma. The latter involves
predefined improvements in organ function—in the case
of renal, a 50% reduction in the total urine protein. Two
patients with biopsy-proven renal primary amyloidosis
underwent stem cell transplantation, and urinary protein
excretion decreased from 7 g/day to less than 2 g/day. A
repeat renal biopsy was performed in both patients, and
persistent glomerular amyloid was present [29].
Unlike multiple myeloma (high plasma cell burden),
most patients with amyloid (low plasma cell burden) do
not receive induction chemotherapy before moving to
stem cell mobilization, bone marrow conditioning, and
finally hematopoietic stem cell transplantation. An ex-
ception is a phase 1/2 study from a group from The
Netherlands involving vincristine, doxorubicin, and dex-
amethasone (VAD) chemotherapy induction. Thirty-
eight patients with amyloidosis were evaluated. Of 12
patients who received transplants, renal involvement was
present in 11. Seven of the nine surviving patients showed
hematologic responses, with organ responses in six of the
nine survivors documented by serum amyloid P scintigra-
phy. Worsening of renal function requiring transient dial-
ysis was seen in one patient. There was one death from a
myocardial infarction after the first course of VAD [30].
The Amyloidosis Center in Pavia, Italy, reported that
cardiac involvement, hypoalbuminemia, and dysautono-
mia with hemodynamic instability increased the proce-
dural risk of mobilization and collection of stem cells.
During collection, 39% of patients had hypotension, and
6.4% of the episodes were life threatening [abstract;
Perotti CG, et al, Blood 102 (Pt 2):415B, 2003]. We
have also found that the morbidity is higher in patients
who undergo stem cell mobilization using chemotherapy
and a growth factor compared with growth factor alone
[31]. Fatal cardiac arrhythmias developed in one patient
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Table 2. Transplantation for renal amyloidosis
Number of Number with
Reference patients renal amyloidosis Comments Outcome
Meier et ala 8 3 Median protein loss 15.7 g/day 6.6 g/day post-stem cell transplant
Snanoudj et al [39] 1 1 Complete response
Casserly et al [40] 15 15 (end-stage renal disease) Treatment-related deaths (N = 2) Complete response (N = 8)
Mollee et alb 48 32 Transplanted (N = 20), seven deaths 3-year survival 56%
Blum et al [41] 13 7 Treatment mortality 15% 2-year survival 47%
aMeier P, Bakr M, Frossard V, et al: Renal outcome in dose-intensive melphalan therapy and autologous stem cell transplantation for AL amyloidosis [abstract]. J
Am Soc Nephrol 13:669A, 2002.
bMollee PN, Wechalekar AD, Pereira DL, et al: Autologous stem cell transplantation (ASCT) in primary systemic amyloidosis (AL): The impact of selection criteria
on outcome [abstract]. Blood 100 (Pt 1):435A, 2002.
whose serum creatinine value was 338 lmol/L during
the infusion of dimethyl sulfoxide cryopreserved stem
cells [32].
Mortality in autologous stem cell transplantation for
amyloid is high, and in our patient population it is 12%.
The serum b 2-microglobulin value, the serum creatinine
value, and the number of organs involved are associ-
ated with treatment-related mortality. Three of our pa-
tients developed postchemotherapy renal insufficiency
and died of dialysis-related complications. Of the 21
treatment-related deaths seen among the 171 patients,
the serum creatinine value of these patients ranged from
79 to 343 lmol/L, with a median of 114 lmol/L. Four of the
21 patients who had treatment-related deaths had a pre-
transplantation creatinine value more than 176 lmol/L
[33]. The best outcomes were seen in patients with single-
organ involvement, predominantly patients with renal
amyloid (115 of the 171) [31].
Transplantation for amyloidosis is associated with
unique toxicities that are not generally seen in patients
who receive transplants for other hematologic malignan-
cies such as multiple myeloma [34]. Toxic megacolon
has been reported in four separate amyloidosis patients,
two of whom had renal amyloid deposits [35]. Intestinal
bleeding is seen in 5% of patients, toxic renal responses
in 8%, and mucositis grade 3 to 4 in 21%, higher than an-
ticipated for patients who undergo transplantation with
nonamyloidotic disease [36]. The risk of death from toxic
response from two or more organ dysfunctions has ap-
proached 75%. In one review, treatment-related mortal-
ity was 30% due to multiorgan failure, gastrointestinal
tract hemorrhage, sepsis, and cardiac complications [37].
The most common serious posttransplantation com-
plication appears to be postconditioning renal insuffi-
ciency. Postconditioning renal insufficiency is defined as
a 50% increase in serum creatinine concentration within
48 hours of conditioning. Age, hypoalbuminemia, heavy
proteinuria, diuretic use, and a urine sediment score
greater than 3 were risk factors. Patients with postcon-
ditioning renal insufficiency were dialyzed more often
and had an inferior 1-year survival. The timing of post-
conditioning renal insufficiency suggests melphalan is the
causal agent. Tubular injury may be a prerequisite for
postconditioning renal insufficiency, as evidenced by the
urinary sediment observed. Postconditioning renal insuf-
ficiency appears to be specific to amyloidosis and is not de-
scribed in other disorders. The exact nature of the injury
remains unclear. It was seen in 15 of 80 patients (19%) in
our cohort [38].
The justification for subjecting patients to a treatment
that carries such potential for morbidity is the excellent
reported outcomes (Table 2). Eight patients were treated
with high-dose melphalan. All eight developed acute
renal failure during the peritransplantation period at a
median of 12 days after stem cell infusion. These eight
required hemodialysis for a median of 6 weeks. All
patients recovered renal function. Serum albumin con-
centration increased in all patients with nephrotic-range
proteinuria. Creatinine clearance did not decrease. Acute
renal failure, when it occurs posttransplantation, is often
a reversible complication. The development of acute re-
nal failure does not preclude an excellent outcome [ab-
stract; Meier P, et al, J Am Soc Nephrol 13:669A, 2002].
In one patient with renal amyloidosis whose pretrans-
plantation serum creatinine concentration was 89 lmol/L
rapidly progressive multiorgan failure developed, includ-
ing anuria and septic shock on day +8. The renal failure
resolved. A hematologic complete response was attained,
and a complete remission of nephrotic-range proteinuria
was achieved [39].
The group at Boston University reported on 15 patients
who came to transplantation with amyloidosis-associated
ESRD. The median survival for the eight responders was
41/2 years. Five patients with a hematologic complete re-
sponse have undergone or are awaiting renal transplanta-
tion. It is feasible for amyloid patients who are on chronic
hemodialysis to undergo transplantation [40].
Patients who are scheduled recipients of a renal al-
lograft are in a special situation relating to stem cell
transplantation. One of the impediments to long-term
successful renal transplantation in amyloidosis is recur-
rent disease in the allografted kidney [42]. We have ap-
plied stem cell transplantation as a means to delay or
reduce the risk of recurrent amyloid in a transplanted
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kidney. At the Mayo Clinic to date, seven patients have
been recipients of high-dose therapy, stem cell transplant,
and renal transplant with the goal of reducing precursor
light chain production, thereby reducing the risk of amy-
loid recurrence. All seven patients were alive from 1.1
to 39.5 months (median 18.7 months). It is too early to
draw any conclusions as to whether this combination of
renal and stem cell transplantation will provide superior
clinical outcomes, but feasibility and safety have been es-
tablished. It is our perception that patients who receive
a stem cell transplant after renal transplantation actually
have reduced morbidity associated with the procedure.
Four of our patients who received transplants had doses
of melphalan of 200 mg/m2, and three had 140 mg/m2. All
patients required hospitalization from 4 to 18 days. Renal
transplantation either after stem cell transplantation or
preceding planned stem cell transplantation is a consid-
eration for patients who develop end-stage renal disease
and have no amyloid outside the kidney [43].
Deciding which patients are candidates for high-dose
therapy is critical. Selection of poor-prognosis patients in-
evitably results in high treatment-related morbidity and
mortality. In a single-center report on 48 patients, only 26
were deemed stem cell transplant candidates. They were
significantly younger, had a better performance status,
and had a trend to better cardiac function than patients
who were not considered candidates for stem cell trans-
plantation. Five patients died during mobilization, and
there was one mobilization failure. Treatment-related
mortality of 35% was reported. Intent-to-treat organ re-
sponse in the kidney was 46%. The 3-year overall post-
stem cell transplantation survival was 56%. The presence
of nephrotic syndrome predicted a better 3-year overall
survival [abstract; Mollee P, et al, Blood 100 (Pt 1):435A,
2002].
In an attempt to reduce the morbidity associated with
stem cell transplantation, we and others have attempted
a risk-adapted approach to therapy [34]. Patients are
classified by performance status, number of organs in-
volved, and severity of organ involvement into cate-
gories of candidates for full-dose therapy, candidates for
reduced-dose therapy, and candidates for conventional
therapy.
In an attempt to further reduce toxic organ responses,
an experimental conditioning regimen of total body irra-
diation alone was developed for patients with amyloido-
sis. The total body irradiation dose was 550 cGy given in
one dose at 30 cGy/min. Noncardiac toxic organ response
was mild. The hematologic complete remission rate was
45%. Conditioning with total body irradiation alone is
feasible and may result in fewer treatment-related com-
plications. Renal responses to the conditioning regimen
of total body irradiation were documented with a reduc-
tion in 24-hour urine protein loss from 12 g to 1.2 g,
17 g to 4.7 g, and 16 g to 1.1 g. Two other patients had
urinary protein responses from the nonnephrotic range
to less than 1 g/day [40].
The patient selection that occurs in determining which
patients are suitable candidates for transplantation intro-
duces inherent selection bias and, therefore, we anticipate
survival for patients receiving a transplant is better than
that for those who do not receive a transplant simply as
a result of selection features alone [44]. In this cohort,
patients who would have been eligible to receive a trans-
plant but were treated conventionally had a median sur-
vival of 42 months and a 5- and 10-year survival of 36%
and 15%, respectively. These results are clearly superior
to what would be expected in terms of survival in an un-
selected cohort of patients with amyloid. Seventy-three
percent of this group had renal amyloidosis, and 37%
had renal amyloid as the only manifestation of disease.
In spite of the inherent superiority of patients eligible for
transplantation, our recently published case-control se-
ries suggested that patients who do receive a transplant
have a better survival than those patients treated conven-
tionally [45].
In conclusion, stem cell transplantation for patients
with renal amyloidosis, including those with end-stage
renal failure, is feasible and results in significant palli-
ation and an improvement in quality of life [46], par-
ticularly in those who achieve a hematologic complete
response. Although the existing data support the use of
high-dose therapy in selected patients, the selection in-
herent in choosing patients represents a favorable prog-
nostic group no matter what treatment they receive. No
phase 3 study data are available to conclusively prove a
response or survival benefit of stem cell transplantation
over conventional therapy in amyloidosis.
Randall-type light chain deposition disease clinically
resembles light chain amyloidosis. Nephrotic syndrome
and ESRD are common. We reviewed the long-term out-
come of renal transplantation in our patients with light
chain deposition disease. Among seven patients, light
chain disease recurred in five. One patient remains alive
on dialysis, four have died, and only one remains recur-
rence free [47]. Renal allograft survival is reduced signif-
icantly unless measures have been taken to reduce light
chain production. In an effort to treat the underlying
plasma cell proliferative disorder, 11 young patients with
light or heavy chain deposition disease received high-
dose therapy. No toxic deaths occurred. A decrease in
monoclonal immunoglobulin levels was observed in eight
patients. Organ manifestations improved in six patients,
including renal, cardiac, and hepatic responses. Histologic
regression of monoclonal immunoglobulin deposits was
documented in the heart, liver, and skin. No manifes-
tations related to the monoclonal immunoglobulin de-
posits occurred or recurred in any patient. Consideration
of high-dose therapy is reasonable in younger patients
with light chain deposition disease. Suppression of light
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chain production may render these patients suitable can-
didates for renal transplantation [48].
TOOLS TO EVALUATE RESPONSE
It was often difficult to determine if patients with
myeloma or amyloid had achieved a response after trans-
plantation. The presence of renal failure often made it
difficult to quantify the urinary loss of monoclonal light
chain used to assess response. In addition, patients with
amyloid as well as light chain myeloma frequently have no
measurable monoclonal protein in the serum. In amyloid
patients with associated nephrotic syndrome, the albu-
minuria made it difficult to estimate absolute quantities
of free light chain in the urine. This obstacle to accurate
response assessment has been reduced recently by the
introduction of the free light chain assay [49, 50]. Now,
serum free light chains can be measured, and the ratio be-
tween the involved and uninvolved light chains is an ex-
cellent correction for the renal insufficiency that results in
reduced light chain excretion. Patients with myeloma who
have renal insufficiency and nearly all patients with amy-
loid who do not have a quantifiable monoclonal protein
can now be assessed by the nephelometric measurement
of free light chain [51].
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